海外の治験の状況「1」での検索結果
51件の検索結果
- 進捗状況
- 試験名
- 対象疾患名
- 地域
- 登録日
Not Available
- The Evaluation of Lamictal as an Add-on Treatment for Bipolar I Disorder in Children and Adolescents, 10 to 17 Years of Age
- Bipolar Disorder MedDRA version: 19.0 Level: HLT Classification code 10004938 Term: Bipolar disorders System Organ Class: 100000004873 ;Therapeutic area: Psychiatry and Psychology [F] - Mental Disorders [F03]
- United States
- 2016-12-21
Not Available
- An open label, 52 week, multicenter study, of long term management to evaluate effectiveness, tolerability and safety of pimecrolimus cream 1% in pediatric patients with mild to moderate atopic dermatitis in a daily practice
- mild to moderate atopic dermatitis;Therapeutic area: Diseases [C] - Skin and Connective Tissue Diseases [C17]
- Mexico, Venezuela, Bolivarian Republic of
- 2017-09-28
Not Available
- A controlled clinical trial to look at the effects of treatment with rufinamide on the body, thought process development and its safety in children aged 1 to 4 years with poorly controlled Lennox Gastaut Syndrome.
- Lennox Gastaut Syndrome MedDRA version: 13.1 Level: PT Classification code 10048816 Term: Lennox-Gastaut syndrome System Organ Class: 10029205 - Nervous system disorders ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]
- France, Greece, India, Italy, United States
- 2011-05-19
Not Available
- First-in-human study of AT132 in X-Linked Myotubular Myopathy (XLMTM) Patients
- X-linked Myotubular Myopathy (XLMTM);Therapeutic area: Diseases [C] - Musculoskeletal Diseases [C05]
- France, Germany, United Kingdom, United States
- 2018-05-25
Not Available
- Raltegravir/Lamivudine Drug Interaction Study
- HIV-1 Infection;Therapeutic area: Body processes [G] - Physiological processes [G07]
- Canada
- 2015-05-22
Not Available
- A Randomized, Multi-center, Blinded, Placebo-controlled Study With an Openlabel Run-in Period to Evaluate the Efficacy, Safety, and Pharmacokinetics of Daily, Single, Subcutaneous Injections of r-metHuiL-1ra (Anakinra) in Polyarticular-Course Juvenile Rheumatoid Arthritis
- Juvenile Rheumatoid Arthritis;Therapeutic area: Diseases [C] - Immune System Diseases [C20]
- Australia, Canada, Costa Rica, New Zealand, United States
- 2015-12-23
Not Available
- A Randomized, Open-Label Study to Evaluate the Pharmacokinetics of Single Oral Doses of Esomeprazole Magnesium in Pediatric Patients 1 to 11 Years-Old Inclusive with Endoscopically-Proven Gastroesophageal Reflux Disease (GERD)
- Pediatric patients 1 to 11 years old, inclusive, with endoscopically-proven GERD. MedDRA version: 14.1 Level: PT Classification code 10017885 Term: Gastrooesophageal reflux disease System Organ Class: 10017947 - Gastrointestinal disorders ;Therapeutic area: Diseases [C] - Digestive System Diseases [C06]
- United States
- 2012-03-08
Not Available
- A 5-month research project for children aged from 1 year to 17 years who have high blood pressure in the lung, to see how well bosentan decreases this high blood pressure and improves children's physical capabilities compared to an inactive compound
- Pulmonary arterial hypertension (PAH) in children MedDRA version: 14.1 Level: LLT Classification code 10064908 Term: Associated with (APAH) System Organ Class: 10038738 - Respiratory, thoracic and mediastinal disorders MedDRA version: 14.1 Level: LLT Classification code 10064909 Term: Idiopathic (IPAH) System Organ Class: 10038738 - Respiratory, thoracic and mediastinal disorders MedDRA version: 14.1 Level: LLT Classification code 10064910 Term: Familial (FPAH) System Organ Class: 10038738 - Respiratory, thoracic and mediastinal disorders ;Therapeutic area: Diseases [C] - Cardiovascular Diseases [C14]
- Argentina, Bulgaria, Chile, China, Colombia, Croatia, France, Guatemala, India, Mexico, Netherlands, Peru, Philippines, Portugal, Russian Federation, Serbia, South Africa, Ukraine, United States, Vietnam
- 2012-02-10
Not Available
- A study to investigate a new medication, NI-0501, in children with the disease systemic Juvenile Idiopathic Arthritis (sJIA) developing Macrophage Activation Syndrome/secondary Hemophagocytic Lymphohistiocytosis (MAS/sHLH)
- Macrophage activation syndrome / Secondary hemophagocytic lymphohistiocytosis (MAS/sHLH) in patients with Systemic Juvenile Idiopathic Arthritis (sJIA) MedDRA version: 20.0 Level: LLT Classification code 10053867 Term: Macrophage activation syndrome System Organ Class: 100000004851 ;Therapeutic area: Diseases [C] - Immune System Diseases [C20]
- Canada, France, Italy, Netherlands, Spain, United Kingdom, United States
- 2017-02-13
Not Available
- Research study to determine whether an investigational drug, SHP647, is safe and effective in the treatment of moderate to severe Crohn’s Disease, compared with placebo (dummy treatment) – using a randomised and blinded study design (investigator and patients are not aware whether they receive study drug or placebo.
- Crohn's disease MedDRA version: 20.0 Level: LLT Classification code 10011402 Term: Crohn's disease (colon) System Organ Class: 100000004856 ;Therapeutic area: Diseases [C] - Digestive System Diseases [C06]
- Argentina, Australia, Austria, Belgium, Bosnia and Herzegovina, Brazil, Bulgaria, Canada, Colombia, Croatia, Czech Republic, Estonia, France, Germany, Greece, Hungary, Ireland, Israel, Italy, Japan, Korea, Republic of, Lithuania, Mexico, Netherlands, New Zealand, Poland, Portugal, Romania, Russian Federation, Serbia, Slovakia, South Africa, Spain, Switzerland, Ukraine, United Kingdom, United States
- 2018-04-10
